November 11, 2006 - La Jolla, California, USA
- One day, 12 speakers, 85 learners, no commercial exhibitors, no posters presented.
- Learner type: 67% Research Scientists, 30% Clinicians, and 3% Other.
- Credit type: ACCME, ANCC and ACPE.
- Recognized experts in the field of melanoma research gathered for this one-day symposium. A unique group of basic and clinical oncologists presented state-of-the-art in immune-based treatments for malignant melanomas.
- 100% of learners reported that the content was free from commercial bias.
- 98% of learners reported that the content was scientifically rigorous.
- 97% of learners reported that they would recommend this program to a colleague.
- Objectives of the course were to:
- Identify the current FDA approved treatments for malignant melanomas.
- List the state-of-the-art in immune-based treatments for malignant melanomas.
- Discuss the advantages and potential toxicities of immune-based treatments for malignant melanoms.
- Review the cellular pathways involved in immunity and autoimmunity in the context of melanoma therapy.
- Selected learner comments included:
- “Broad spectrum, high level scientific contributions.”
- “Nice mix of enthusiastic presenters.”
- “Good overview of technology and state of art.”
- “Outstanding program – I learned a lot and hope it happens again.”
- “Too local”
- “In a short period of time review immunotherapy for melanoma.”
- “Building a scientific community can only help.”
- “Very informative, interesting, but too much basic research, very little clinical relevance.”
- “New treatment options aside from current therapies. More advanced technology in the pipeline – we as a clinician should know about.”
- Selected comments about the speakers included:
- “Excellent – clear.”
- “Very important for affiliation in humans.”
- “Excellent speaker, simplifies complicated concepts, interesting presentation.”
- “Too technical.”
- “Excellent speakers and conclusions.”
Disclosures of Faculty Relationships
BioSymposia, Inc. (formerly Serono Symposia International, Inc.) adheres to guidelines of the Accreditation Council for Continuing Medical Education (ACCME), the American Nurses Credentialing Center’s Commission on Accreditation (ANCCCA), the Accreditation Council for Pharmaceutical Education (ACPE), and all other professional organizations as applicable, stating that programs where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
As uses for pharmaceutical agents, medical devices, and other products may be presented in the program that are not necessarily the same as those indicated in approved product labeling (but which may reflect clinical experience, professional literature, other clinical sources known to the presenter, or investigational uses of products), we ask the presenter to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is simply intended to inform participants of any potential conflicts so that participants may form their own judgments based on full disclosure of the facts. Further, these opinions and recommendations presented during the program or materials related to the program do not imply an endorsement or recommendation on the part of BioSymposia, Inc. These presentations solely represent the independent views of the presenters/authors.
The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-FDA approved (off-label) uses of drugs:
Gregory Daniels discloses that his introduction will include off-label or otherwise non-approved uses of products that are in clinical trials (Vidaza, Intereferon, MDX-010).
Steffan Ho discloses that his talk contains information about healthcare products or services that are associated with Biogen Indec, Inc, with whom he has a financial relationship.
Ann Moriarty discloses she is an employee of Johnson & Johnson.
Atoni Ribas discloses that his lecture will include off-label or otherwise non-approved uses of products (MDX-010, CP-675206, CP-870893, CHIR-1212, BMS-66513), and that his CME content contains information about healthcare products (CP-675206) or services that are in connection with a financial relationship (research grant and honoraria).
Heather Wilcox discloses she is an employee of MediVas, LLD.
The following faculty indicated no significant relationship with commercial supporters and/or discussion of investigational or non-FDA approved (off-label) uses of drugs:
Linda Bradley, Kasper Hoebe, Edith Janssen, Michael Karin, Thomas Kipps, Mitchell Kronenberg, Davorka Messmer, and Maurizio Zanetti.
Commercial Support and Other Disclosures
BioSymposia, Inc. (formerly Serono Symposia International, Inc.) is a 501(c)3 non-profit organization. All of our programs are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted. There may be presentations discussing investigational uses of various products. These views are the responsibility of the named speakers and do not represent an endorsement or recommendation on the part of BioSymposia, Inc.
This program was supported by an unrestricted educational grant from EMD Serono, Inc. In addition, BioSymposia personnel are employees of EMD Serono, Inc. and BioSymposia, Inc. also receives other in-kind support from EMD Serono, Inc. in the form of space and administrative services.
Printer friendly version Overcoming Barriers to Immune Therapy in Melanoma
